TY - T1 - Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin SN - / UR - http://hdl.handle.net/10138/334461 T3 - A1 - Ylösmäki, Erkko; Fusciello, Manlio; Martins, Beatriz; Feola, Sara; Hamdan, Firas; Chiaro, Jacopo; Ylösmäki, Leena; Vaughan, Matthew J.; Viitala, Tapani; Kulkarni, Prasad S.; Cerullo, Vincenzo A2 - PB - Y1 - 2021 LA - eng AB - Background Intratumoral BCG therapy, one of the earliest immunotherapies, can lead to infiltration of immune cells into a treated tumor. However, an increase in the number of BCG-induced tumor-specific T cells in the tumor microenvironment could lead to enhanced therapeutic effects. Methods Here, we have developed a novel cancer vaccine platform based on BCG that can broaden BCG-induced immune responses to include tumor antigens. By physically attaching tumor-specific peptides onto the mycobacte... VO - IS - SP - OP - KW - adaptive immunity; immunity; cellular; immunogenicity; vaccine; immunotherapy; active; ADVANCED MELANOMA PATIENTS; MYCOBACTERIUM-BOVIS BCG; PRIME-BOOST VACCINATION; TOPICAL IMIQUIMOD; IMMUNE-RESPONSES; SURFACE-CHARGE; B16 MELANOMA; TUMOR-GROWTH; VIRUS; IMMUNOTHERAPY; 3122 Cancers; 317 Pharmacy N1 - PP - ER -